compani
wrap lower po conserv
price key product
growth driver miss price/competit dynam
although ep roughli in-lin our/con estimate lower po due top-line
miss key growth driver remov tanezumab pain forecast notabl
trim est trulic diabet taltz immunolog base lower net
price outlook due increasingli competit end-market updat po
vs prior reflect lower price-to-earnings multipl due
tanezumab remov reduc ep lower mainli driven taltz
declin forecast base soft net sale trend slightli lower assum
lower net price volum launch abbv skyrizi erbitux estimate
decreas lower ex-u royalti follow expiri licens agreement merck
kgaa updat trulic moder estimate
miss minim chang expect volum growth off-set
price discount tanezumab remov forecast recent long-term safeti
data indic low probabl approv altern approv oner
restrict reit neutral given lli premium valuat balanc risk/reward
takeaway confer call
highlight us rebat reform continu believ rebat reform would
provid favor outcom pharma new scheme expect drive volum
growth assumpt lower patient out-of-pocket cost would lead better medic
adher overal expect net impact reform neutral compani
trulic diabet management indic step chang price last
quarter cite q/q headwind declin shipment depress otherwis
soft result higher averag free product channel expect sale
benefit improv commerci reimburs rate note exit
compar averag taltz immunolog management field sever question
taltz follow sale miss recent competitor launch abbv skyrizi management
view skyrizi categori expand direct threat remain confid growth
outlook cite post-market studi indic expans rewind studi cv
outcom trulic compani plan host investor call ada medic
meet review detail rewind data follow formal present rewind
focu ada less emphasi tirzepitid follow-on trulic dose-
titrat data dose escal scheme differ protocol
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
timestamp april edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani april
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani april
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani april
